On the risk of delisting of ordinary shares of Prelude Therapeutics Incorporated (PRLD)

The International Trading System Limited (hereinafter — ITS) hereby informs on the information concerning delisting risk of ordinary shares of Prelude Therapeutics Incorporated (ISIN US74065P1012, hereinafter — Shares) from The Nasdaq Stock Market LLC (hereinafter — Nasdaq).

Information on delisting risk of ordinary shares by Nasdaq

On March 28, 2025 Prelude Therapeutics Incorporated (hereinafter – the Company) submitted Current report on Form 8-K to The United States Securities and Exchange Commission (hereinafter – SEC). According to the report, on March 27, 2025 the Company received a notice from Nasdaq indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the minimum bid price of the Company’s common stock had been below $1.00 per share for the last 30 consecutive business days.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until September 23, 2025 to regain compliance with the Minimum Bid Price Requirement. If the Company does not regain compliance with the Minimum Bid Price Requirement by the Compliance Date, the Company may be eligible for an additional 180 calendar day compliance period.

To regain compliance, the closing bid price for the Common Stock must be at least $1.00 per share for a minimum of ten consecutive business days before the Compliance Date. If the Company fails to regain compliance prior to the expiration of the extension period, Nasdaq will provide written notification that the Company’s securities will be delisted. For more information, please refer to the report available on the SEC website.

Information regarding possible actions to be taken by ITS Ltd.

If Nasdaq suspends trading in the Company’s ordinary shares, ITS will prohibit submission of orders and will restrict ability to conclude agreements in respect of the Company’s ordinary shares. If the Company’s ordinary shares are delisted from Nasdaq, ITS will terminate trading in the Company’s ordinary shares. However, in case the Company’s ordinary shares become listed, or admitted to trading on another Recognised Trading Venue, ITS will consider but does not guarantee continuation of trading in the Company’s ordinary shares.